US House Committee approves medical liability reform

18 February 2011

In the USA, the House of Representatives Judiciary Committee passed legislation - HR 5, the Help Efficient, Accessible, Low-cost, Timely Healthcare (HEALTH) Act (The Pharma Letter January 24) – on Wednesday by a vote of 18 to 15 and the bill now goes to the full House of Representatives for consideration.

The bill, focussing on ways to eliminate “frivolous” law suits against medical personnel, was introduced by Committee Chairman Lamar Smith (Republican, Texas) The Congressional Budget Office estimates that medical liability reform would result in costs savings to the US federal budget of $54 billion over the next 10 years.

The bill imposes a $250,000 cap on subjective, non-economic damages; collateral source rule reform allowing evidence of outside payments to be made in court; a ban on subrogation by collateral sources; a fee schedule for attorney contingency fees; and imposes periodic payments of future damages.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical